BACKGROUND: Conventional hemodialysis (HD) is associated with profound disturbances in calcium and phosphate metabolism and abnormal parathyroid hormone (PTH) levels. Effects of more frequent HD on calcium and phosphate balance have not been fully elucidated. METHODS: The London Daily/Nocturnal Hemodialysis Study examined effects of quotidian HD, either daily HD (n = 11) or nocturnal HD (n = 12), on calcium and phosphate metabolism, bone alkaline phosphatase levels, and intact PTH (iPTH) levels. RESULTS: Daily HD patients showed a slight decrease in predialysis serum phosphate levels, no changes in phosphate-binder requirements or serum calcium levels, and slight increases in serum bone alkaline phosphatase and iPTH levels. Nocturnal HD patients showed a trend for decreased predialysis phosphate levels, with significantly lower values than daily HD and matched control patients on conventional HD therapy at several times. Phosphate-binder use by nocturnal HD patients was significantly reduced. Both quotidian HD groups showed decreases in calcium x phosphate product, with significantly lower values for nocturnal HD patients (38.11 mg(2)/dL(2)) compared with daily HD and control patients (53.99 and 52.51 mg(2)/dL(2), respectively) at 18 months. Bone alkaline phosphatase levels increased slightly and attained statistical significance compared with baseline values for both quotidian HD groups. A trend for increases in serum iPTH levels, coupled with increasing levels of bone alkaline phosphatase in nocturnal HD patients, led to the decision to increase the dialysate calcium concentration from 5.0 to 7.0 mg/dL. This 1-time adjustment resulted in a reversal of the trend and a return to baseline values. CONCLUSION: This study shows the superior control of serum phosphate levels in nocturnal HD patients compared with daily HD or conventional HD patients and the benefits of dialysate with a greater calcium concentration in slow nocturnal HD.
BACKGROUND: Conventional hemodialysis (HD) is associated with profound disturbances in calcium and phosphate metabolism and abnormal parathyroid hormone (PTH) levels. Effects of more frequent HD on calcium and phosphate balance have not been fully elucidated. METHODS: The London Daily/Nocturnal Hemodialysis Study examined effects of quotidian HD, either daily HD (n = 11) or nocturnal HD (n = 12), on calcium and phosphate metabolism, bone alkaline phosphatase levels, and intact PTH (iPTH) levels. RESULTS: Daily HDpatients showed a slight decrease in predialysis serum phosphate levels, no changes in phosphate-binder requirements or serum calcium levels, and slight increases in serum bone alkaline phosphatase and iPTH levels. Nocturnal HDpatients showed a trend for decreased predialysis phosphate levels, with significantly lower values than daily HD and matched control patients on conventional HD therapy at several times. Phosphate-binder use by nocturnal HDpatients was significantly reduced. Both quotidian HD groups showed decreases in calcium x phosphate product, with significantly lower values for nocturnal HDpatients (38.11 mg(2)/dL(2)) compared with daily HD and control patients (53.99 and 52.51 mg(2)/dL(2), respectively) at 18 months. Bone alkaline phosphatase levels increased slightly and attained statistical significance compared with baseline values for both quotidian HD groups. A trend for increases in serum iPTH levels, coupled with increasing levels of bone alkaline phosphatase in nocturnal HDpatients, led to the decision to increase the dialysate calcium concentration from 5.0 to 7.0 mg/dL. This 1-time adjustment resulted in a reversal of the trend and a return to baseline values. CONCLUSION: This study shows the superior control of serum phosphate levels in nocturnal HDpatients compared with daily HD or conventional HDpatients and the benefits of dialysate with a greater calcium concentration in slow nocturnal HD.
Authors: John T Daugirdas; Glenn M Chertow; Brett Larive; Andreas Pierratos; Tom Greene; Juan Carlos Ayus; Cynthia A Kendrick; Sam H James; Brent W Miller; Gerald Schulman; Isidro B Salusky; Alan S Kliger Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Johan M Lorenzen; Thomas Thum; Georg M Eisenbach; Hermann Haller; Jan T Kielstein Journal: Int Urol Nephrol Date: 2011-02-27 Impact factor: 2.370
Authors: Daljit K Hothi; Elizabeth Harvey; Elizabeth Piva; Laura Keating; Donna Secker; Denis F Geary Journal: Pediatr Nephrol Date: 2006-04-01 Impact factor: 3.714
Authors: William H Fissell; Anna Dubnisheva; Abigail N Eldridge; Aaron J Fleischman; Andrew L Zydney; Shuvo Roy Journal: J Memb Sci Date: 2009-01-05 Impact factor: 8.742
Authors: Dominik Müller; Miriam Zimmering; Christopher T Chan; Philip A McFarlane; Andreas Pierratos; Uwe Querfeld Journal: Pediatr Nephrol Date: 2008-03-12 Impact factor: 3.714